Yang Shuofei, Fan Xinxin, Ding Weiwei, Liu Baochen, Meng Jiaxiang, Xu Dandan, He Changsheng, Yu Wenkui, Wu Xingjiang, Li Jieshou
Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China; Department of Vascular Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China; Integrated Intestinal Stroke Center, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China.
Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China; Department of Vascular Surgery, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China; Department of Gastroenterology, Inflammatory Bowel Diseases, Nutritional Support and Intestinal Transplantation, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China; Integrated Intestinal Stroke Center, Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, Jiangsu Province, P. R. China.
Thromb Res. 2015 Jan;135(1):36-45. doi: 10.1016/j.thromres.2014.10.018. Epub 2014 Nov 10.
Acute superior mesenteric venous thrombosis (ASMVT) is an uncommon but catastrophic abdominal vascular emergency with high rate of intestinal failure and mortality. The retrospective pilot study was performed to assess the effect of a multidisciplinary stepwise management strategy on survival and mesenteric recanalization in an integrated intestinal stroke center (ISC).
A modern management strategy performed by multidisciplinary specialists in ISC was evaluated among 43 ASMVT patients that were classified into central vs peripheral type, operative vs nonoperative, early vs late treated group from March 2009 to April 2013. Patients received specific medical therapy, endovascular treatment, damage-control surgery, selective second-look laparotomy, critical care management, and clinical nutrition support in a stepwise way. The demographics, etiology, imaging characteristics, treatment procedures, complications, clinical outcome, and 1-year follow-up data were analyzed and compared. Confounding factors of mortality were identified by univariate and ROC-curve analysis. A single-center experience of over 5years for this modern strategy was also reported.
The protocol of multidisciplinary stepwise management strategy was followed in all ASMVT patients successfully. The 30-day mortality and recanalization rate were 11.63% and 90.70%. Initial damage-control surgery was carried out in 46.51% patients, with selective second-look laparotomy in 23.26% patients. Endovascular thrombolysis was performed in 83.72% patients initially or postoperatively. Bowel resection was necessary in 18 patients with the length of 100.00 (47.50, 222.50) cm. The incidence of short-bowel syndrome was 13.95%. The rate and length of bowel resection, short-bowel syndrome rate were significantly lower in nonoperative and early-treated groups (P<0.05). During the follow-up survey, 1-year survival was 83.72%, with no additional death or re-thrombosis.
A multidisciplinary stepwise management strategy involving modern surgical and endovascular treatments that focus on early mesenteric recanalization and bowel viability salvage in a specialized ISC could significantly improve the clinical outcome of ASMVT patients.
急性肠系膜上静脉血栓形成(ASMVT)是一种罕见但灾难性的腹部血管急症,肠衰竭和死亡率很高。本回顾性前瞻性研究旨在评估多学科逐步管理策略对综合肠道卒中中心(ISC)患者生存及肠系膜再通的影响。
2009年3月至2013年4月期间,对43例ASMVT患者评估了由ISC多学科专家实施的现代管理策略,这些患者被分为中心型与外周型、手术治疗组与非手术治疗组、早期治疗组与晚期治疗组。患者按序接受特定的药物治疗、血管内治疗、损伤控制手术、选择性二次剖腹探查、重症监护管理及临床营养支持。分析并比较了人口统计学、病因、影像学特征、治疗过程、并发症、临床结局及1年随访数据。通过单因素及ROC曲线分析确定死亡率的混杂因素。还报告了该现代策略5年以上的单中心经验。
所有ASMVT患者均成功遵循多学科逐步管理策略方案。30天死亡率和再通率分别为11.63%和90.70%。46.51%的患者接受了初始损伤控制手术,23.26%的患者接受了选择性二次剖腹探查。83.72%的患者在初始或术后接受了血管内溶栓治疗。18例患者需要行肠切除术,切除肠管长度为100.00(47.50,222.50)cm。短肠综合征发生率为13.95%。非手术治疗组和早期治疗组的肠切除率、切除肠管长度、短肠综合征发生率显著较低(P<0.05)。随访期间,1年生存率为83.72%,无额外死亡或再发血栓形成。
在专门的ISC中,采用包括现代外科和血管内治疗的多学科逐步管理策略,注重早期肠系膜再通及挽救肠管活力,可显著改善ASMVT患者的临床结局。